Vext ScienceVEXTF 71 ROE % is -6.50% as of Mar. 2026. GuruFocus rates VEXTF with a GF Score™ of 71/100 and a GF Value™ of $1.08 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 935 Drug Manufacturers companies, Vext Science ranks worse than 85.67% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Vext Science's annualized net income for the quarter that ended in Mar. 2026 was $-3.57 Mil. Vext Science's average Total Stockholders Equity over the quarter that ended in Mar. 2026 was $54.93 Mil. Therefore, Vext Science's annualized ROE % for the quarter that ended in Mar. 2026 was -6.50%.
The historical rank and industry rank for Vext Science's ROE % or its related term are showing as below:
VEXTF'
s ROE % Range Over the Past 10 Years
Min: -27.96 Med: 10.42 Max: 46.8
Current: -23.99
During the past 9 years, Vext Science's highest ROE % was 46.80%. The lowest was -27.96%. And the median was 10.42%.
VEXTF's ROE % is ranked worse than 85.67% of 935
companies
in the Drug Manufacturers industry
Industry Median: 6
vs VEXTF: -23.99
Vext Science (OTCPK:VEXTF) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Vext Science ROE % Related Terms
Vext Science ROE % Historical Data
* Premium members only.
The historical data trend for Vext Science's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vext Science's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vext Science ROE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vext Science's ROE % distribution charts can be found below:
* The bar in red indicates where Vext Science's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Vext Science (VEXTF) has a ROE % of -6.50% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Vext Science and its competitors. According to the industry distribution chart, Vext Science ranks #801 out of 935 companies in the Drug Manufacturers industry, placing it in the top 85.7%.
Is Vext Science's ROE % too high?
Vext Science's current ROE % is -6.50%. Based on the distribution chart, Vext Science ranks #801 out of 935 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Vext Science has a GF Score™ of 71/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vext Science's ROE % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vext Science ranks #801 out of 935 companies for ROE %. This places Vext Science in the lower half of its industry. The industry median ROE % is 6.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Drug Manufacturers company?
The median ROE % among Drug Manufacturers companies is 6.00, based on 935 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Vext Science and its competitors. For the Drug Manufacturers industry, the median ROE % is 6.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vext Science's current ROE % is -6.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vext Science stock overvalued right now?
Based on GuruFocus' analysis, Vext Science (VEXTF) is currently considered Possible Value Trap. The stock's GF Value™ is $1.08, compared to a current price of $0.16 — trading 84.9% below its estimated fair value. The current ROE % is -6.50%. Vext Science's overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Vext Science (VEXTF), the current ROE % is -6.50% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vext Science (VEXTF) Overvalued in 2026?
Based on GuruFocus' analysis, Vext Science stock appears to be undervalued.
The current stock price of $0.16 is trading 84.9% below its estimated GF Value™ of $1.08.
GuruFocus considers Vext Science to be Possible Value Trap.
Key valuation signals for VEXTF:
ROE %: -6.50%
GF Value™: $1.08 vs. price of $0.16 (84.9% below fair value)
No single metric tells the full story. See the VEXTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vext Science Inc engages in the full spectrum of the cannabis product lifecycle, from development and manufacturing to distribution. Its brands include Herbal Wellness, Appalachian Pharm, Revibe, Prism, Vapen, and Firebrand. In Arizona and Ohio, the dispensaries operate under the Herbal Wellness Center brand, while in Ohio the cultivation and manufacturing operations are licensed and branded as Appalachian Pharms Cultivation and Appalachian Pharm Processing. The Company operates through a single operating segment engaged in the cultivation, manufacturing, distribution, and sale of cannabis within the United States. All revenues are generated in the United States.
71GF Score
Get the complete analysis for VEXTF
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VEXTF has been successfully added to your 
